Results from EBV CTL trials in SOT recipients with PTLDs
| Study ID author (y) . | CTL type . | Number of patients . | Median age (range) . | Types of SOTs, n . | PTLD subtype, n . | EBV response . | Response rates . | Survival . | Length of follow-up . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Prockop46 (2020) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 13 | 10 y (0.7-75.2) | Kidney, 5 Heart, 3 Liver, 2 Small bowel, 1 Heart + liver, 1 | mPTLD, 8 pPTLD, 4 HL-like, 1 | Undetectable in 7 of 13 patients | ORR, 54.8% CR, 2 of 13 PR, 5 of 13 | Patients with SD 1 y survival = 81.8% Patients with PR/CR 1 y survival = 88.9% | 115 mo |
| Kazi47 (2019) | HLA-matched, third party | 20 | 31 y (1-82) | Kidney, 10 Liver, 3 Heart, 2 Small bowel, 1 Small bowel, 1 Pancreas, 1 | Not specified | Not reported | ORR, 75% CR, 10 of 20 PR, 5 of 20 | Median, 3.87 y | 6 mo | |
| Chiou48 (2018) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 11 | 40 mo (12-144) | Liver, 5 Small bowel + liver, 5 Liver + kidney, 1 | mPTLD, 7 pPTLD, 2 HL-like PTLD, 1 Unspecified, 1 | Undetectable in all patients | ORR, 73.7% CR, 7 of 11 PR, 1 of 11 | Overall, 5 y 85.7% | 14 y |
| Vickers49 (2014) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 4 | 18.5 y (1-53) | Kidney, 1 Heart, 1 Liver, 1 Heart + kidney, 1 | Not specified | Not reported | ORR, 100% CR, 4 of 4 | Not reported | Not reported |
| Gallot50 (2014) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 3 | 45 y (42-60) | Heart, 1 Heart + lung, 1 Kidney, 1 | mPTLD, 3 | Not reported | ORR, 66% CR, 1 of 3 | Not reported | Not reported |
| Haque44 (2007) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 31 | 41 y (1-76) | Kidney, 13 Liver, 10 Liver + small bowel, 3 Heart, 2 Lung, 2 Heart + lung, 1 | mPTLD, 11 pPTLD, 7 Hyperplastic PTLD, 7 HL-like PTLD, 5 Burkitt PTLD, 1 | Decreased in 10 patients | ORR, 48.4% CR, 12 of 31 PR, 3 of 31 | 2 y OS, 30% | 7.5 y |
| Gandhi51 (2007) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 3 | 52 y (18-58) | Kidney, 1 Heart + lung, 1 Lung, 1 | mPTLD, 2 pPTLD, 1 | Undetectable in 2 of 3 | ORR, 66.7% CR, 2 | 106 days | 249 d |
| Savoldo52 (2006) | HLA-matched, third party | Autologous EBV-specific CTL | 6 | 2.5 y (0-35 y) | Liver, 4 Heart, 2 | Unspecified, 4 PTLD, 2 | Decreased in 4 patients | ORR, 100% CR, 1 of 6 PR, 5 of 6 | OS, 100% | 6 mo |
| Comoli53 (2005) | HLA-matched, third party | Autologous EBV-specific CTL | 5 | 11 y (2-14) | Kidney, 5 | mPTLD, 2 pPTLD, 1 Plasmacytoma, 1 Hyperplasia PTLD. 1 | From 0 to 300 copies | ORR, 100% CR, 5 of 5 | OS, 100% | 31 mo |
| Study ID author (y) . | CTL type . | Number of patients . | Median age (range) . | Types of SOTs, n . | PTLD subtype, n . | EBV response . | Response rates . | Survival . | Length of follow-up . | |
|---|---|---|---|---|---|---|---|---|---|---|
| Prockop46 (2020) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 13 | 10 y (0.7-75.2) | Kidney, 5 Heart, 3 Liver, 2 Small bowel, 1 Heart + liver, 1 | mPTLD, 8 pPTLD, 4 HL-like, 1 | Undetectable in 7 of 13 patients | ORR, 54.8% CR, 2 of 13 PR, 5 of 13 | Patients with SD 1 y survival = 81.8% Patients with PR/CR 1 y survival = 88.9% | 115 mo |
| Kazi47 (2019) | HLA-matched, third party | 20 | 31 y (1-82) | Kidney, 10 Liver, 3 Heart, 2 Small bowel, 1 Small bowel, 1 Pancreas, 1 | Not specified | Not reported | ORR, 75% CR, 10 of 20 PR, 5 of 20 | Median, 3.87 y | 6 mo | |
| Chiou48 (2018) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 11 | 40 mo (12-144) | Liver, 5 Small bowel + liver, 5 Liver + kidney, 1 | mPTLD, 7 pPTLD, 2 HL-like PTLD, 1 Unspecified, 1 | Undetectable in all patients | ORR, 73.7% CR, 7 of 11 PR, 1 of 11 | Overall, 5 y 85.7% | 14 y |
| Vickers49 (2014) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 4 | 18.5 y (1-53) | Kidney, 1 Heart, 1 Liver, 1 Heart + kidney, 1 | Not specified | Not reported | ORR, 100% CR, 4 of 4 | Not reported | Not reported |
| Gallot50 (2014) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 3 | 45 y (42-60) | Heart, 1 Heart + lung, 1 Kidney, 1 | mPTLD, 3 | Not reported | ORR, 66% CR, 1 of 3 | Not reported | Not reported |
| Haque44 (2007) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 31 | 41 y (1-76) | Kidney, 13 Liver, 10 Liver + small bowel, 3 Heart, 2 Lung, 2 Heart + lung, 1 | mPTLD, 11 pPTLD, 7 Hyperplastic PTLD, 7 HL-like PTLD, 5 Burkitt PTLD, 1 | Decreased in 10 patients | ORR, 48.4% CR, 12 of 31 PR, 3 of 31 | 2 y OS, 30% | 7.5 y |
| Gandhi51 (2007) | HLA-matched, third party | EBV-BLCL–sensitized EBV CTLs | 3 | 52 y (18-58) | Kidney, 1 Heart + lung, 1 Lung, 1 | mPTLD, 2 pPTLD, 1 | Undetectable in 2 of 3 | ORR, 66.7% CR, 2 | 106 days | 249 d |
| Savoldo52 (2006) | HLA-matched, third party | Autologous EBV-specific CTL | 6 | 2.5 y (0-35 y) | Liver, 4 Heart, 2 | Unspecified, 4 PTLD, 2 | Decreased in 4 patients | ORR, 100% CR, 1 of 6 PR, 5 of 6 | OS, 100% | 6 mo |
| Comoli53 (2005) | HLA-matched, third party | Autologous EBV-specific CTL | 5 | 11 y (2-14) | Kidney, 5 | mPTLD, 2 pPTLD, 1 Plasmacytoma, 1 Hyperplasia PTLD. 1 | From 0 to 300 copies | ORR, 100% CR, 5 of 5 | OS, 100% | 31 mo |
BLCL, B lymphoblastic cell line; SD, stable disease.